SAKAR Sakar Healthcare Q1 FY27 results (Apr–Jun 2026) and concall
Sakar Healthcare Limited reported strong Q1 FY27 results, with significant year-on-year growth in revenue, EBITDA, and PAT. The company's oncology division showed robust momentum through new product contracts, dossier submissions, and marketing authorizations, particularly in export markets. Management is focused on expanding its oncology-led export franchise and improving margins through backward integration, with expectations of substantial growth in the coming years without major new capex.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q1 FY27: revenue up 37.7%, net profit up 100.0% against the same quarter last year.
| Line item | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|
| Revenue | 43 | 50 | 53 | 58 | 70 +63% | 71 +42% | 73 +38% |
| EBITDA | 12 | 16 | 13 | 11 | 19 +58% | 26 +63% | 21 +62% |
| Net profit | 5 | 6 | 5 | 5 | 10 +100% | 11 +83% | 10 +100% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
